- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05998135
Gjenbruk atovaquone for behandling av platinaresistent eggstokkreft
Fase II klinisk studie med gjenbruk av atovakvon for behandling av platinaresistent eggstokkreft
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine progression free survival of twenty-eight patients with platinum-resistant ovarian cancer treated with atovaquone.
SECONDARY OBJECTIVES:
I. To determine clinical benefit rate (complete response, partial response or stable disease) at six months.
II. To determine overall survival. III. To quantitate the on-target STAT3 inhibitory effect of atovaquone on STAT3-dependent gene transcription.
IV. To quantitate changes of the tumor immune infiltrate by inhibition of STAT3 with atovaquone.
OUTLINE:
Patients receive atovaquone orally (PO) on study. Patients also undergo computed tomography (CT) and biopsy or paracentesis throughout the study.
After completion of study treatment, patients are followed up for 30 days and then every 6 month thereafter.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Namita Khanna, MD, MSPH
- Telefonnummer: 404-778-3401
- E-post: namita.khanna@emory.edu
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital/Winship Cancer Institute
-
Ta kontakt med:
- Nina Kimball
- Telefonnummer: 404-778-8145
- E-post: nina.cathleen.dobbs.kimball@emory.edu
-
Ta kontakt med:
- Maisey S Ratcliffe
- Telefonnummer: 404-778-3449
- E-post: maisey.shannon.ratcliffe@emory.edu
-
Hovedetterforsker:
- Namita Khanna, MD, MSPH
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
- Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- There will be no limitations on number of prior lines of therapy
- Trial is open to non-English speaking patients
- Trial is open to patients referred from community practice
Exclusion Criteria:
- Patients who are < 18 years old
- Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
- Patients who are incarcerated
- Patients who are unable to provide consent / lack decision-making capacity
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment (atovaquone)
Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study. |
Undergo CT
Andre navn:
Undergo biopsy
Andre navn:
Undergo paracentesis Given PO
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression free survival (PFS)
Tidsramme: From initiation of atovaquone to progression or death, assessed up to 1 year
|
Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median PFS will be estimated using the Brookmeyer-Crowley approach. |
From initiation of atovaquone to progression or death, assessed up to 1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical benefit rate
Tidsramme: At 6 months
|
Clinical benefit rate is defined as complete response, partial response, and/or stable disease at six months. Clinical response will be assessed every 6 weeks for the first 24 months and every 12 weeks thereafter using Response Evaluation Criteria in Solid Tumors 1.1 criteria. Will be estimated as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. |
At 6 months
|
|
Overall survival (OS)
Tidsramme: From diagnosis to death from any cause, where patients who are alive will be censored at last follow-up date, assessed up to 1 year
|
OS will be estimated using the Kaplan-Meier method, and median survival will be calculated. A 95% confidence interval will be estimated using the Brookmeyer-Crowley approach. |
From diagnosis to death from any cause, where patients who are alive will be censored at last follow-up date, assessed up to 1 year
|
|
Incidence of adverse events
Tidsramme: Up to 30 days
|
Safety will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. Frequencies and percentages will be used to summarize safety events. |
Up to 30 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Namita Khanna, MD, MSPH, Emory University Hospital/Winship Cancer Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Organiske kjemikalier
- Undersøkelsesteknikker
- Terapeutikk
- Prøvehåndtering
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Punkteringer
- Kirurgiske prosedyrer, operativ
- Cytologiske teknikker
- Cytodiagnose
- Naftalener
- Polysykliske aromatiske hydrokarboner
- Polysykliske forbindelser
- Diagnostiske teknikker, kirurgisk
- Kinoner
- Naftokinoner
- Drenering
- Atovaquone
- Biopsi
- Paracentesis
Andre studie-ID-numre
- STUDY00005363
- P30CA138292 (U.S. NIH-stipend/kontrakt)
- STUDY00005363 (Annen identifikator: Emory University)
- NCI-2023-03479 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- WINSHIP5782-22 (Annen identifikator: Emory University)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .